Results 271 to 280 of about 177,883 (410)

Exercise evokes retained motor performance without neuroprotection in a mouse model of Parkinson's disease. [PDF]

open access: yesFront Physiol
Skelton HM   +7 more
europepmc   +1 more source

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

open access: yesMovement Disorders, EarlyView.
Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova   +5 more
wiley   +1 more source

Microbiota and Guillain-Barré syndrome: role of microbial metabolites, biomarkers, and emerging therapeutic strategies. [PDF]

open access: yesFront Neurol
Zurdo-López M   +4 more
europepmc   +1 more source

A Curcumin-Decorated Nanozyme with ROS Scavenging and Anti-Inflammatory Properties for Neuroprotection [PDF]

open access: gold
Feng Gao   +8 more
openalex   +1 more source

Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease [PDF]

open access: gold, 2019
Ewelina Pałasz   +5 more
openalex   +1 more source

Neuroprotective Effects of RNS60 in TDP‐43 Pathology‐Associated Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction TDP‐43 pathology is broadly observed in the cerebral cortex of patients with amyotrophic lateral sclerosis (ALS). RNS60, an experimental treatment for acute ischemic stroke and ALS, enhanced mitochondrial biogenesis and function in other preclinical models.
Danny R. Vesevick   +4 more
wiley   +1 more source

Brosimine B and the biphasic dose-response: insights into hormesis and retinal neuroprotection [PDF]

open access: gold
Susanne Suely Santos da Fonseca   +12 more
openalex   +1 more source

Home - About - Disclaimer - Privacy